Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
May 2023
in “
Cureus
”
New to Alopecia Areata? There is a guide in the encyclopedia. Read the guide → 
Studysummary In this case report, a 64-year-old woman developed alopecia areata after starting the IL-17A inhibitor secukinumab for psoriasis, highlighting a potential rare side effect of this treatment, with only three similar cases reported in the literature. Our plain-language summary of this paper — not a Tressless recommendation.
This case report discusses a 64-year-old female patient who developed alopecia areata (AA) after starting secukinumab, an IL-17A inhibitor, for her plaque psoriasis. The report suggests a potential link between IL-17A inhibitors and the onset of AA, highlighting a rare but significant side effect. This is one of only three case reports that specifically address the association between IL-17A inhibitors and AA, indicating the need for further investigation into this potential side effect.
